These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908 [TBL] [Abstract][Full Text] [Related]
11. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis? Scott IC; Kingsley GH; Scott DL Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S4-8. PubMed ID: 24129128 [TBL] [Abstract][Full Text] [Related]
12. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448 [TBL] [Abstract][Full Text] [Related]
13. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Kavanaugh A; Wells AF Rheumatology (Oxford); 2014 Oct; 53(10):1742-51. PubMed ID: 24729402 [TBL] [Abstract][Full Text] [Related]
14. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: A systematic review and meta-analysis of randomised trials. Palmowski A; Pankow A; Terziyska K; Nielsen SM; Christensen R; Bliddal H; Boyadzhieva Z; Buttgereit F Semin Arthritis Rheum; 2024 Feb; 64():152349. PubMed ID: 38100900 [TBL] [Abstract][Full Text] [Related]
15. The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis. Cutolo M; Spies CM; Buttgereit F; Paolino S; Pizzorni C Arthritis Res Ther; 2014 Nov; 16 Suppl 2(Suppl 2):S1. PubMed ID: 25608624 [TBL] [Abstract][Full Text] [Related]
16. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491 [TBL] [Abstract][Full Text] [Related]
17. Long term effectiveness of RA-1 as a monotherapy and in combination with disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis. Chopra A; Saluja M; Kianifard T; Chitre D; Venugopalan A J Ayurveda Integr Med; 2018; 9(3):201-208. PubMed ID: 29526468 [TBL] [Abstract][Full Text] [Related]
18. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461 [TBL] [Abstract][Full Text] [Related]
19. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646 [TBL] [Abstract][Full Text] [Related]
20. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]